Sylvia McBrinn

Background

About Sylvia McBrinn

I am a public company Board Director, former CEO and Commercialization expert with 30+ years of leadership experience in the BioPharma industry. With a strong commercial background in the U.S. and global markets, I have led successful launches of specialty to blockbuster products and grown market share for companies including Pfizer and Vernalis. I provide biopharmaceutical companies critical insights from a career of executive governance, operational and commercial success across a wide range of therapeutic areas, including Neurology, Inflammation and Rheumatology, Pain, Infectious Disease/Microbiome, and Urology. Currently, I serve and advise BioAtla (Nasdaq: BCAB) as Board Director, Compensation Committee Chair and Audit Committee member. Until recently, I was a board director at Ilya Pharma (private), I led as Board Director/founding CEO of early-stage biotech, Axerion Therapeutics (now ReNetX Bio), and also built and led the US Subsidiary of a British Biotech, Vernalis with full P&L oversight. Earlier, I was the EVP and GM of Andrx with full P&L responsibility, overseeing branded products with 400 employees across key business functions. Throughout my career and board roles, I have earned a reputation of a strategic thinker with the ability to connect the dots and ask insightful questions between business direction, portfolio strategy, R&D, marketing and Commercialization. As Global VP of Marketing at Pfizer, I led the launch and commercialization of the blockbuster product Bextra – the #1 Product launch in the US that year – achieving $1B in sales first 12 months and exceeding forecast by 35%. Additionally, I built the #1 Parkinson’s disease product franchise globally, exceeding forecast by 40%. At Vernalis, I in-licensed and relaunched Apokyn, an injectable Parkinson’s product that increased sales 42% YOY. I am a passionate supporter of women, innovators, and entrepreneurs in business. In addition to Board service, I guide and mentor women entrepreneurs with their pitch and strategy as a member of Springboard Enterprises Life Science Council to accelerate growth of entrepreneurial, women led companies. I also serve as a “sounding board” for Yale innovators contemplating a startup, as Entrepreneur in Residence at Yale University Office of Cooperative Research. Specialties: Pharmaceuticals | Biotechnology | Entrepreneurship & Startups | P&L | New Product Commercialization | Strategic Product Development | Strategic Marketing | Globalization | Financing | Business Development | Partnering | Licensing | Public Company Board governance